IP Library Granted Patent US 6,974,806
Granted Patent B2
US 6,974,806 · App. 10/332,632 · Granted Dec 13, 2005

Lipid-rich plaque inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,974,806
App. No.
10/332,632
Granted
Dec 13, 2005
Kind
B2
Abstract

The present invention provides a lipid-rich plaque regressing agent comprising a compound represented by Formula: in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is —NR 1 — (in which R 1 is a hydrocarbon or the like); D is a C 1-3 alkylene group or the like; E is —NH— or the like; G is a bond or the like; and Ar is an aryl or the like; D may be taken together with a constituent atom of the ring B to form a ring, and R 4 may be taken together with a constituent atom of the ring B to form a ring.

Claims (10)

1. A compound selected from the group consisting of:

(2E)-3-[3-[7-chloro-3-(2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]propenoic acid;

(2E)-3-[3-[7-chloro-3-(2-[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]propenoic acid; and

3-[3-[7-chloro-3-(2-[[4-chloro-2-(trifluorornethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]propanoic acid, or a salt thereof.

2. A pharmaceutical composition comprising a compound according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent.

3. A method for regressing a lipid-rich plaque in a mammal in need thereof, comprising administering an effective amount of a compound according to claim 1 or a salt.

4. A method for treating acute coronary artery syndrome in a mammal in need thereof, comprising administering an effective amount of a compound of claim 1 or a salt thereof, to said mammal.

5. A method for treating acute myocardial infarction in a mammal in need thereof, comprising administering an effective amount of a compound of claim 1 or a salt thereof, to said mammal.

6. A method for treating unstable angina in a mammal in need thereof, comprising administering an effective amount of a compound of claim 1 or a salt thereof, to said mammal.

7. A method for treating peripheral artery occlusion in a mammal in need thereof, comprising administering an effective amount of a compound of claim 1 or a salt thereof, to said mammal.

Assignments (2)
CHANGE OF NAME Recorded May 16, 2005
From: TAKEDA CHEMICAL INDUSTRIES, LTD.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 016891/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2003
From: TERASHITA, ZEN-ICHI; NAKAMURA, MASAHIRA; MARUI, SHOGO; OGINO, MASAKI
To: TAKEDA CHEMICAL INDUSTRIES LTD.
Reel/Frame 013976/0672 →